Wellington Management Group
TPTX

Wellington Management Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Wellington Management Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,910,170
Closed -$144M – 2225
2022
Q2 		$144M Sell
1,910,170
-2,120,821
-53% -$94.2M 0.03% 456
2022
Q1 		$108M Buy
4,030,991
+21,337
+0.5% +$717K 0.02% 566
2021
Q4 		$191M Buy
4,009,654
+602,179
+18% +$26.9M 0.03% 454
2021
Q3 		$226M Sell
3,407,475
-42,334
-1% -$3.02M 0.04% 413
2021
Q2 		$269M Buy
3,449,809
+1,347,965
+64% +$99.6M 0.04% 377
2021
Q1 		$199M Sell
2,101,844
-131,901
-6% -$15.7M 0.04% 428
2020
Q4 		$272M Buy
2,233,745
+22,174
+1% +$2.43M 0.05% 337
2020
Q3 		$193M Sell
2,211,571
-72,301
-3% -$5.04M 0.04% 369
2020
Q2 		$148M Buy
2,283,872
+733,857
+47% +$42.3M 0.03% 426
2020
Q1 		$69.2M Buy
+1,550,015
New +$82.3M 0.02% 542

Wellington Management Group's TPTX Position: Q3 2022 in Review

Wellington Management Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,910,170 shares — an estimated $144M sold.

Wellington Management Group first reported a position in TPTX in Q1 2020 and held it in 10 quarters. The position peaked at $272M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Wellington Management Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Wellington Management Group sold 1,910,170 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $144M.
  • Wellington Management Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
  • Wellington Management Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $272M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Wellington Management Group's 13F filing for Q3 2022, filed 14 Nov 2022.